Aclaris Therapeutics Inc (NASDAQ: ACRS) has seen a decline in its stock price by -1.23 in relation to its previous close of 1.22. However, the company has experienced a -10.07% decline in its stock price over the last five trading sessions. zacks.com reported 2024-08-07 that Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.42 per share a year ago.
Is It Worth Investing in Aclaris Therapeutics Inc (NASDAQ: ACRS) Right Now?
Moreover, the 36-month beta value for ACRS is 0.28. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ACRS is 65.48M and currently, short sellers hold a 3.30% of that float. On August 07, 2024, ACRS’s average trading volume was 882.08K shares.
ACRS’s Market Performance
ACRS stock saw a decrease of -10.07% in the past week, with a monthly decline of -4.37% and a quarterly a decrease of -10.07%. The volatility ratio for the week is 5.45%, and the volatility levels for the last 30 days are 5.25% for Aclaris Therapeutics Inc (ACRS). The simple moving average for the last 20 days is -8.64% for ACRS stock, with a simple moving average of -18.81% for the last 200 days.
Analysts’ Opinion of ACRS
Evercore ISI gave a rating of “Outperform” to ACRS, setting the target price at $22 in the report published on October 03rd of the previous year.
ACRS Trading at 0.27% from the 50-Day Moving Average
After a stumble in the market that brought ACRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.89% of loss for the given period.
Volatility was left at 5.25%, however, over the last 30 days, the volatility rate increased by 5.45%, as shares sank -4.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.46% upper at present.
During the last 5 trading sessions, ACRS fell by -9.33%, which changed the moving average for the period of 200-days by -77.16% in comparison to the 20-day moving average, which settled at $1.3162. In addition, Aclaris Therapeutics Inc saw 14.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACRS starting from Leonard Braden Michael, who purchase 206,025 shares at the price of $1.24 back on Aug 05 ’24. After this action, Leonard Braden Michael now owns 14,250,000 shares of Aclaris Therapeutics Inc, valued at $256,357 using the latest closing price.
Leonard Braden Michael, the 10% Owner of Aclaris Therapeutics Inc, purchase 167,544 shares at $1.29 during a trade that took place back on Aug 02 ’24, which means that Leonard Braden Michael is holding 14,043,975 shares at $216,400 based on the most recent closing price.
Stock Fundamentals for ACRS
Current profitability levels for the company are sitting at:
- -2.61 for the present operating margin
- 0.66 for the gross margin
The net margin for Aclaris Therapeutics Inc stands at -2.48. The total capital return value is set at -0.53. Equity return is now at value -48.47, with -38.27 for asset returns.
Based on Aclaris Therapeutics Inc (ACRS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -20.95. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -50.67.
Currently, EBITDA for the company is -134.41 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 1.69. The receivables turnover for the company is 83.43for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.74.
Conclusion
To wrap up, the performance of Aclaris Therapeutics Inc (ACRS) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
